http://www.unboundmedicine.com/medline/ebm/research/risedronateUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.http://www.unboundmedicine.com/medline/ebm/record/19925985/full_citation/Correlation_Between_Serum_C_Terminal_Cross_Linking_Telopeptide_of_Type_I_Collagen_and_Staging_of_Oral_Bisphosphonate_Related_Osteonecrosis_of_the_Jaws_Kwon YD, Kim DY, Ohe JY, et al. 
Correlation Between Serum C-Terminal Cross-Linking Telopeptide of Type I Collagen and Staging of Oral Bisphosphonate-Related Osteonecrosis of the Jaws. [JOURNAL ARTICLE]
J Oral Maxillofac Surg 2009 Dec; 67(12):2644-2648.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19925895/full_citation/Bisphosphonate_Treatment_Modifies_Canine_Bone_Mineral_and_Matrix_Properties_and_their_Heterogeneity_Gourion-Arsiquaud S, Allen MR, Burr DB, et al. 
Bisphosphonate Treatment Modifies Canine Bone Mineral and Matrix Properties and their Heterogeneity. [JOURNAL ARTICLE]
Bone 2009 Nov 16.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19904734/full_citation/Differences_between_bisphosphonates_in_binding_affinities_for_hydroxyapatite_Lawson MA, Xia Z, Barnett BL, et al. 
Differences between bisphosphonates in binding affinities for hydroxyapatite. [JOURNAL ARTICLE]
J Biomed Mater Res B Appl Biomater 2009 Nov 10.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19898839/full_citation/Prescription_of_anti_osteoporosis_drugs_during_2004_2007_a_nationwide_register_study_in_Norway_Devold HM, Doung GM, Tverdal A, et al. 
Prescription of anti-osteoporosis drugs during 2004-2007-a nationwide register study in Norway. [JOURNAL ARTICLE]
Eur J Clin Pharmacol 2009 Nov 7.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19883401/full_citation/The_Impact_of_Fewer_Hip_Fractures_with_Risedronate_Versus_Alendronate_in_the_First_Year_of_Treatment:_Modeled_German_Cost_Effectiveness_Analysis_Thompson M, Pasquale M, Grima D, et al. 
The Impact of Fewer Hip Fractures with Risedronate Versus Alendronate in the First Year of Treatment: Modeled German Cost-Effectiveness Analysis. [JOURNAL ARTICLE]
Value Health 2009 Oct 26.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19859641/full_citation/Use_of_bisphosphonates_and_raloxifene_and_risk_of_deep_venous_thromboembolism_and_pulmonary_embolism_Vestergaard P, Schwartz K, Pinholt EM, et al. 
Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism. [JOURNAL ARTICLE]
Osteoporos Int 2009 Oct 27.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19857619/full_citation/Bisphosphonates_do_not_inhibit_periosteal_bone_formation_in_estrogen_deficient_animals_and_allow_enhanced_bone_modeling_in_response_to_mechanical_loading_Feher A, Koivunemi A, Koivunemi M, et al. 
Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading. [JOURNAL ARTICLE]
Bone 2009 Oct 23.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19853678/full_citation/The_Effect_of_Risedronate_on_Hip_Structural_Geometry_in_Chemotherapy_Induced_Postmenopausal_Women_on_SERMs_versus_Aromatase_Inhibitors:_a_Two_Year_Trial_van Londen GJ, Perera S, Vujevich KT, et al. 
The Effect of Risedronate on Hip Structural Geometry in Chemotherapy-Induced Postmenopausal Women on SERMs versus Aromatase Inhibitors: a Two Year Trial. [JOURNAL ARTICLE]
Bone 2009 Oct 21.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19845802/full_citation/Osteoporosis_management:_a_perspective_based_on_bisphosphonate_data_from_randomised_clinical_trials_and_observational_databases_Boonen S, Kay R, Cooper C, et al. 
Osteoporosis management: a perspective based on bisphosphonate data from randomised clinical trials and observational databases. [JOURNAL ARTICLE]
Int J Clin Pract 2009 Oct 20.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19835464/full_citation/Update_on_monthly_oral_bisphosphonate_therapy_for_the_treatment_of_osteoporosis:_focus_on_ibandronate_150_mg_and_risedronate_150_mg_Epstein S, Jeglitsch M, McCloskey E 
Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. [JOURNAL ARTICLE]
Curr Med Res Opin 2009 Oct 16.
Abstract | Full Citation | Find Related Articles